The American Academy of Pediatrics recommends lipid-lowering therapy (LLT) for children at high risk of cardiovascular disease. However, the use of LLT in children is rare, and rates of nonadherence are unknown.
Introduction
The National Heart, Lung, and Blood Institute and American Academy of Pediatrics (AAP) recommend lipid-lowering therapy (LLT) for treatment of severe dyslipidemia in children aged 8 to 10 years when diet and exercise have failed to sufficiently reduce low-density lipoprotein cholesterol (LDL-C).
1,2 However, these recommendations are controversial, and the use of LLT in children and adolescents is rare. 3, 4 In adults, the benefit of LLT in reducing the risk of cardiovascular disease (CVD) depends considerably on medication adherence. Yet, adherence to LLT is low or moderate with long-term rates between 36% and 88%. [5] [6] [7] [8] [9] [10] [11] Similar to adults, there is evidence to suggest that in children, the benefits of LLT require consistent use and that the risk of CVD in children and adolescents is cumulative. [12] [13] [14] For example, a recent study by Ference et al., found that subjects who had prolonged exposure to lower LDL-C levels early in life as a result of a gene-variant had fewer coronary events relative to subjects who began LDL-C lowering with statins later in life. These findings were consistent even when the same LDL-C levels were achieved, suggesting that early treatment may reduce the risk of CVD by preventing the early and irreversible buildup of plaque. 13 To date, however, the only study of adherence to LLT during childhood is a 10-year follow-up study of 214 children who participated in a 2-year clinical trial for the safety and efficacy of pravastatin. 15 Although the authors found that 88.8% of study subjects were still using LLT after 10 years, the generalizability of the results to the population outside the clinical trial setting is limited. 16 Interest in population based measures of medication adherence during childhood has grown as the prevalence of chronic conditions in childhood has increased over the past two decades. 17 However, studies have found mixed results with rates of adherence ranging from 25% to 88%. 18, 19 Furthermore, research has tended to focus on childhood conditions in which nonadherence can result in serious acute effects, such as asthma or diabetes. [19] [20] [21] In contrast, the benefits of LLT during childhood are unlikely to be realized for another 20 to 30 years, resulting in substantially different incentives for medication adherence. Thus, studies of other chronic medications during childhood may not be applicable, and additional work is needed to identify possible avenues for improvement in very high-risk children, especially those with genetic dyslipidemias.
The objective of this study was to describe patterns of prescribing and adherence to LLT in a population of commercially insured children aged 8 to 20 years in both the full cohort of children prescribed LLT during the study period as well as the subgroup of patients with a diagnosis for dyslipidemia. To achieve this objective, we used a large national database of private insurance claims between 2003 and 2013, a period in which the recommendations for pharmacologic treatment transitioned from the 1992 NCEP and 1998 AAP guidelines recommending bile acid sequestrants as first line agents to the 2008 AAP and 2011 NHLBI guidelines, which recommended statins as a first line treatment.
Methods
Data sources and study population Database is a database of employer-based health insurance claims that contains all reimbursable health care claims, including prescription medication dispensings, filled for employees and their dependents.
Our study population consisted of all enrollees aged 8 to 20 years who met two criteria: (1) a new LLT dispensing, defined as the first (''index'') dispensing after a minimum of 12 months of continuous enrollment (the baseline period), and (2) a minimum 12 months of follow-up time after the index dispensing. We assessed the presence of the following clinical conditions before the index dispensing: dyslipidemia, diabetes, obesity, hypertension, metabolic syndrome, asthma, chronic kidney disease (CKD), depression, and attention deficit hyperactive disorder. A condition was considered present if the patient had two outpatient claims within a 24-month period, with the first occurring before the index dispensing, or a single inpatient claim before the index dispensing. Additionally, we measured the following prescription drug dispensings and measures of health care utilization in the year before the index dispensing; prescription dispensings for diabetes, hypertension, asthma, depression, and antipsychotics; the presence of a recorded screening for diabetes or a lipid panel; and the number of outpatient, inpatient, and prescription drug dispensings other than LLT.
Classification of LLT
We classified each LLT dispensing first by class (statins, nonstatins, statin combinations, and nonstatin combinations, which included both single pill combinations and different class dispensings, which occurred within 7 days of each other) and then by the specific drug within each class. We calculated the proportion of patients with more than one dispensing during the follow-up period by the type of index dispensing. Among patients with multiple dispensings, we further identified the presence of subsequent switching or adding of a medication different from the index class.
Measures of nonadherence
An episode of nonadherence was defined as a gap of a minimum 90 days between the last covered day of treatment and the next filled prescription or the end of follow-up. Covered days of treatment were calculated by adding the days supply for the prescription to the date the prescription was filled. If a prescription was filled early, the overlap was added to the number of days supply based on the assumption that the patient would start the new prescription once the current prescription was finished. We defined the start of nonadherence conservatively as the date of last dispensing plus the days supply, which assumes that the patient took the full course of LLT before discontinuing (Fig. 1) . 22 Gaps ,90 days were not counted as nonadherent and although patients could reinitiate treatment, patients were censored after the first nonadherent episode. In sensitivity analyses, this definition was extended to 120 days.
Analysis
Patient level covariates were compared across type of index LLT using chi-square tests for comparisons. KaplanMeier curves were used to estimate time to nonadherence stratified by the presence of a dyslipidemia diagnosis and the index LLT class. Nonstatin combinations were omitted from Kaplan-Meier analyses due to small sample size.
Multivariable Cox-proportionate hazard models were used to estimate the hazard of nonadherence in the full population and the subpopulation of patients with a dyslipidemia diagnosis. Multivariable Cox models were adjusted for (1) age sex, type of index LLT; (2) a diagnosis of dyslipidemia, obesity, hypertension, metabolic syndrome, diabetes, asthma, CKD, depression or attention deficit hyperactive disorder; (3) a prescription drug dispensing within the 12 months before the index date for an antihypertensive, antiasthmatic, antidiabetic, antidepressant, or antipsychotic; (4) a recorded diabetes screening or lipid panel; (5) measures of health utilization in the 12 months before the index dispensing including outpatient, inpatient, and prescription drugs other than LLT. All analyses were conducted using SAS, 9.4 (Cary, NC).
Results

Baseline characteristics and initial LLT patterns
There were a total of 19,157,497 children aged 8 to 20 years between 2004 and 2012 with at least 2 years of continuous enrollment. Of these, we identified 8710 children and adolescents with a new dispensing for LLT between 2005 and 2012 who had at least 12 months of continuous enrollment without a dispensing for an LLT before the index dispensing (new users) and a minimum 12 months of follow-up after the index dispensing. Among children initiating LLT, most patients were first prescribed a statin (51.2%) or a nonstatin (44.1%), with a small proportion receiving prescriptions for combination therapy (4.5% statin and nonstatin combination, and 0.2% nonstatin combination; Table 1 ). Compared to patients with an index dispensing for a nonstatin, patients with an index statin dispensing were more likely to have diagnosed comorbidities with the exception of depression. Patients with an index dispensing for a statin were also more likely to have dispensings for other studied medications (except antipsychotics), to have been screened for diabetes or had a lipid panel, to have received more than one Figure 1 Timeline of LLT therapy illustrating definition of treatment nonadherence. T 1 represents the date of the index prescription. At T 32 , the patient refills the prescription, leaving a 2-day gap in the end of the first prescription and start of the second. However, because this gap is ,90 days, the patient is not considered to have had an episode of nonadherence. The patient then fills the next prescription at T 55 , 7 days earlier than the end of the second prescription at T 62 . This overlap of seven days is then added to the 30 days supply and the end of covered treatment days is now T 92 (T 55 1 7 days of overlap 1 30-day supply). The next prescription is filled at T 200 , which is .90 days from the end of the last covered day of treatment (T 92 ) and thus, the patient is considered to be nonadherent on day 92. outpatient visit, and to have a prescription drug dispensing other than LLT in the past year (P , .001 for all comparisons; Table 1 ). Results were similar with respect to comorbidities and health care utilization for patients with an index dispensing for a statin combination as compared to a nonstatin (Table 1) .
Among patients with an index dispensing of statins, the most common prescriptions were atorvastatin (37%) or simvastatin (35%; Table 2 ). Among patients with an index dispensing of nonstatins, the majority were prescribed bile acid sequestrants (59%), whereas approximately a quarter of patients (29%) were prescribed fibric acid derivatives.
The most commonly prescribed statin combination was statin plus ezetimibe (75%; Table 2 ).
Patterns of nonadherence
Although the proportion of patients with an initial dispensing for statins and nonstatins were comparable, 76% of statin users had a second dispensing versus only 50% of nonstatin users (Table 2) . Among those with an index dispensing for statins, there proportion receiving second dispensings varied from 66.7% for Fluvastatin to 78.1% for Pravastatin. In contrast, among patients with an index dispensing for nonstatins, the proportion with second dispensings varied ranged from 36.8% for bile acid sequestrants to 78% for ezetimibe. Among patients with 2 or more dispensings, switching or adding a different type of LLT after the index prescription was uncommon, with ,10% of patients switching from a statin to a nonstatin or vice versa (supplementary table 1 ). During follow-up (median 5 30 months, interquartile range [IQR] 5 20-48), at least one episode of nonadherence occurred in 7583 (87%) patients. Of these, 6864 (90%) of the nonadherence episodes occurred within the first year after the index dispensing. Patients with a recorded diagnosis of dyslipidemia were less likely to have a nonadherence episode compared to patients without a dyslipidemia diagnosis (P , .001 by the log-rank test), although this difference was slightly attenuated, yet still statistically significant, after the first year (unadjusted hazard ratio [HR] 5 0.50, 95% CI 5 0.48-0.53 in the first year, compared to HR 5 0.76, 95% CI 5 0.65-0.88 after the first year; Fig. 2, panel A) .
Compared to an index dispensing of nonstatin medications, an index dispensing of statins or statin combinations was less likely to be followed by nonadherence episode (P , .001 by the log-rank test). Again, this effect was stronger in the first year after the index dispensing (HR comparing statin vs nonstatin users 5 0.58, 95% CI 5 0.56-0.61 in the first 12 months vs HR 5 0.81, 95% CI 5 0.68-0.96 after 12 months; HR comparing statin combination vs nonstatin users: HR 5 0.44, 95% CI 5 0.39-0.50 in the first 12 months vs HR 5 0.57 95% CI 5 0.42-0.77 after 12 months; Fig. 2, panel B) . With respect to specific medicines, bile acid sequestrants were commonly discontinued, whereas nonadherence did not differ by specific statin (Fig. 2, panels C and D) .
In multivariable analyses, older adolescents (HR 5 1.06, 95% CI 5 1.01-1.13) were more likely to be nonadherent, 
Discussion
In a large, national database of private insurance claims, we found that despite recommendations to begin continuous treatment for high-risk children and adolescents, LLT use is rare and those who do initiate treatment tend to become nonadherent within the first year. Specifically, we found that among children and adolescents aged 8 to There were no niacin and bile acid sequestrant nonstatin combinations. experienced an episode of nonadherence during a median follow-up time of 30 months with 90% of those patients experiencing an episode of nonadherence in the first year after the index dispensing.
Although not studied to the extent it is in adults, medication adherence in childhood is gaining prominence as the percent of children with a chronic illness has increased over the past two decades, 23 and studies have pointed out the need for additional information on predictors of adherence. 19, 20, 24, 25 Our results suggest that high-risk patientsthose with dyslipidemia, CKD, outpatient, and inpatient care and prescription drug use-are less likely to have an episode of nonadherence, as are patients whose index dispensing is a statin combination, which may reflect that combination patients are more severely dyslipidemic, although greater tolerability of statin combination drugs cannot be ruled out. However, even among patients with the most possible to gain from LLT use, rates of adherence were low.
Although we could not confirm a diagnosis of FH among patients with dyslipidemia, 55% of patients with dyslipidemia in our sample had a claim specifically for pure hypercholesterolemia (ICD-9 code 272.0), which includes FH as well as other causes of hypercholesterolemia. The low rates of adherence in our analysis may explain why studies have found that among children prescribed statins both with and without a diagnosis of FH, stabilization of LDL-C at 130 mg/dL was low. 26 When we limited the sample to only patients with dyslipidemia, only age and obesity were associated with greater adherence, suggesting that a diagnosis of dyslipidemia alone is a strong predictor of adherence, regardless of whether patients experience additional risk factors. Our results are consistent with those found in adults, in which patients taking LLT for primary prevention are less likely to be adherent than secondary prevention patients, such as the patients with dyslipidemia in our population. 8 The distribution of index prescriptions by LLT class is notable given the relatively high frequency of nonstatin dispensings in this population (44.1% of all index dispensings). Although generally efficacious, bile acid sequestrants were removed from first line therapy status in guidelines released in Figure 2 Cumulative percent of patients with an episode of medication nonadherence lasting at least 90 days stratified by (A) a diagnosis of dyslipidemia, (B) the index dispensing's class of LLT, (C) the type of nonstatin LLT index dispensing among patients whose index dispensing was a nonstatin, (D) the type of statin index dispensing among patients whose index dispensing was a statin.
2008 and 2011 due to comparatively poor tolerability. 2, 27, 28 However, fibric acid derivatives are not approved and not widely recommended for use in children, and Niacin is explicitly cautioned against for use in children due to the high prevalence of serious side effects. 2, 27 The relatively high frequency of nonstatin prescribing may reflect a lack of familiarity among providers with the updated AAP and NLBI guidelines, both of which recommend prescription of statins to children over other forms of lipid-lowering therapy such as bile acid sequestrants. 29 Indeed, the higher rate of statin relative to nonstatin dispensings in males than in females is consistent with previous hypotheses that statins might interfere with cholesterol-derived sex hormones and consequent sexual maturation, although multiple studies in children with familial hypercholesterolemia have shown sex hormones and development to be largely unaffected. 15, 30 In addition to gender, there were significant differences inpatient characteristics between patients with an index statin or statin-combination dispensing as compared to an index nonstatin dispensing. In particular, the lower prevalence of a recorded diagnosis of dyslipidemia in the nonstatin group as well as the low prevalence of multiple dispensings after an index dispensing for a bile acid sequestrant suggest that some proportions of prescribing may be for conditions other than dyslipidemia, such as chronic diarrhea. 31 Similarly, given the high prevalence of concomitant medications, it is possible that LLT is being prescribed to address increases in lipid levels secondary to temporary medical conditions or medication use and thus would only be prescribed for a limited time period, however appropriate or inappropriate. 32 The risk of side effects associated with statin use is low, suggesting that the high rates of nonadherence are not likely due to side effects. However, it is also possible that the relatively higher rates of nonadherence among nonstatin initiators may reflect the poorer tolerability in this class of LLT. 1, 2, 27 There is no single accepted method for measuring adherence to medication, and often the choice of method depends on the goal of the analysis. 22, 33 Patients who discontinue medication may have been highly persistent users up until that point, whereas other patients may have much more intermittent use but never fully discontinue medication use. Interventions to increase medication adherence are increasingly focused on identifying characteristics associated with nonadherence and tailoring approaches toward individuals. 34 Our finding that patients with greater physician contact before their index dispensing have higher rates of adherence suggests that there may be an important role for providers in developing interventions.
Although not directly addressed in our analysis, medication adherence in childhood can also be influenced by the parent-child dynamic. For example, parental concern over asthma medication is associated with lower rates of adherence, 35, 36 and as children gain more autonomy during adolescence, rates of adherence to chronic medication decline, which is in-line with our finding that older patients were more likely to be nonadherent. 37, 38 Indeed studies demonstrating the influence of parental beliefs on child adherence to medication would suggest that identifying parental characteristics associated with nonadherence may be important in increasing adherence in children. 35 Because of their large size and comprehensive information on prescription medications that are filled, administrative databases are frequently used in the study of medication adherence. However, it is important to note their limitations. First, it is not possible to confirm that patients are actually taking medication, only that they are refilling prescriptions. However, a study comparing prescription refill rates with electronic devices that monitor the date and time when a medication container is opened, found concordance of the measures. 33 Prescription refill rates are also notably better for measure adherence to chronic medications, such as statins, than to acute medication such as a short course of antibiotics. 23 Second, we used a measure of nonadherence based on a minimum gap of 90 days after the last covered day of treatment. A previous study of adherence to statins in Ontario adults used a gap period of 120 days; however, the maximum prescription available was 100 days, allowing for a 20% grace period. 8 The days supply for prescriptions in our database ranged from 30 to 90 days, and thus, our measure is as, or more, conservative than prior studies. Moreover, sensitivity analyses using the 120-day definition did not substantially change identified predictors. Although there are limitations to our study, our methods are consistent with previous studies of adherence to LLT in adults 8, 10 , and our sample came from a population of over 19 million privately insured children aged 8 to 20 years, making it generalizable to the commercially insured population.
Notwithstanding the controversy over LLT use in children and adolescents, the benefits of treatment cannot be realized unless medication is used consistently. Unlike adults, where even short-term adherence of 1 to 2 years can significantly reduce the risk of an acute cardiovascular event, the benefits of LLT initiated in childhood are based on the assumption of continued use over a long period of time. 39 Our results show high rates of nonadherence in this population, suggesting that to realize the benefits of LLT, interventions to increase adherence are needed.
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